BioCentury
ARTICLE | Clinical News

Amonafide L-malate: Development discontinued

February 7, 2011 8:00 AM UTC

Antisoma discontinued development of amonafide after data from the open-label, international Phase III ACCEDE trial in over 420 patients showed that 600 mg/m 2 IV amonafide for 5 days plus cytarabine ...